PCP: From pharmacology to modelling schizophrenia

Current Opinion in Pharmacology

Volumn 5, Issue 1, 2005, Pages 101-106

  Morris, Brian J ^a,b   Cochran, Susan M ^a   Pratt, Judith A ^a,c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIZOCILPINE; GLUTAMATE RECEPTOR; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE;

CENTRAL NERVOUS SYSTEM; DELIRIUM; DISORIENTATION; DRUG EFFICACY; DRUG STRUCTURE; HALLUCINATION; HUMAN; MENTAL PATIENT; NEUROANATOMY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; RODENT; SCHIZOPHRENIA; SPEECH DISORDER;

ANIMALS; HALLUCINOGENS; HUMANS; MODELS, BIOLOGICAL; PHENCYCLIDINE; PHENCYCLIDINE ABUSE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 12344326762     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2004.08.008     Document Type: Review

References (62)

1. C.M. Adler A.K. Malhotra I. Elman T. Goldberg M. Egan D. Pickar A. Breier Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia Am J Psychiatry 156 1999 1646-1649
2. E.D. Luby B.D. Cohen G. Rosenbaum J.S. Gottlieb R. Kelly Study of a new schizophrenic-like drug: Sernyl Sernyl Archives of Neurological Psychiatry 81 1959 363-369
3. R.M. Allen S.J. Young Phencyclidine-induced psychosis Am J Psychiatry 135 1978 1081-1084
4. J.H. Krystal L.P. Karper J.P. Seibyl G.K. Freeman R. Delaney J.D. Bremner G.R. Heninger M.B.J. Bowers D.S. Charney Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry 51 1994 199-214
5. N.A. Anis S.C. Berry N.R. Burton D. Lodge The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-aspartate Br J Pharmacol 79 1983 565-575
6. A.V. Ferrer-Montiel J.M. Merino R. Planells-Cases W. Sun M. Montal Structural determinants of the blocker binding site in glutamate and NMDA receptor channels Neuropharmacology 37 1998 139-147
7. X. Zheng L. Zhang A.P. Wang R.C. Araneda Y. Lin R.S. Zukin M.V.L. Bennett Mutation of structural determinants lining the N-methyl-D-aspartate receptor channel differentially affects phencyclidine block and spermine potentiation and block Neuroscience 93 1999 125-134
8. M.G. Lacey G. Henderson Actions of phencyclidine on rat locus coeruleus neurones in vitro Neuroscience 17 1986 485-494
9. J. Ffrench-Mullen M. Rogawski Interaction of phencyclidine with voltage-dependent potassium channels in cultured rat hippocampal neurons: Comparison with block of the NMDA receptor-ionophore complex J Neurosci 9 1989 4051-4061
10. D.N. Bailey Phencyclidine abuse. Clinical findings and concentrations in biological fluids after nonfatal intoxication Am J Clin Pathol 72 1979 795-799
11. J.P. Vincent J.N. Bidard M. Lazdunski G. Romey Y. Tourneur J. Vignon Identification and properties of phencyclidine-binding sites in nervous tissues Fed Proc 42 1983 2570-2573
12. R. Oswald M. Bamberger J. McLaughlin Mechanism of phencyclidine binding to the acetylcholine receptor from Torpedo electroplaque Mol Pharmacol 25 1984 360-368
13. P.C. Contreras M.L. Contreras T.L. O'Donohue C.C. Lair Biochemical and behavioral effects of sigma and PCP ligands Synapse 2 1988 240-243
14. D. Pubill D. Gasulla F.X. Sureda A. Camins M. Pallas E. Escubedo J. Camarasa Characterization of [3H]nisoxetine binding in rat vas deferens membranes: Modulation by sigma and PCP ligands Life Sci 62 1998 763-773
15. R.E. Garey R.G. Heath The effects of phencyclidine on the uptake of 3H-catecholamines by rat striatal and hypothalamic synaptosomes Life Sci 18 1976 1105-1110
16. B.P. Sokolov Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free schizophrenics: Evidence on reversible up-regulation by typical neuroleptics J Neurochem 71 1998 2454-2464
17. J.T. Noga T.M. Hyde M.M. Herman C.F. Spurney L.B. Bigelow D.R. Weinberger J.E. Kleinman Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains Synapse 27 1997 168-176
18. F. Sams-Dodd Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test Behav Pharmacol 8 1997 196-215
19. B. Adams B. Moghaddam Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine J Neurosci 18 1998 5545-5554
20. R.S. Mansbach M.A. Geyer Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat Neuropsychopharmacology 2 1989 299-308
21. J.D. Jentsch D.E. Redmond Jr. J.D. Elsworth J.R. Taylor K.D. Youngren R.H. Roth Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine Science 277 1997 953-955
22. J.D. Jentsch A. Tran D. Le K.D. Youngren R.H. Roth Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat Neuropsychopharmacology 17 1997 92-99
23. J.W. Olney J. Labruyere M.T. Price Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs Science 244 1989 1360-1362
24. D.A. Lewis GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia Brain Res Brain Res Rev 31 2000 270-276
25. J.N. Pierri A.S. Chaudry T.U. Woo D.A. Lewis Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects Am J Psychiatry 156 1999 1709-1719
26. C.L. Beasley G.P. Reynolds Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics Schizophr Res 24 1997 349-355
27. Z.J. Zhang G.P. Reynolds A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia Schizophr Res 55 2002 1-10
28. E.A. Hazlett M.S. Buchsbaum E. Kemether R. Bloom J. Platholi A.M. Brickman L. Shihabuddin C. Tang W. Byne Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia Am J Psychiatry 161 2004 305-314
29. E.A. Hazlett M.S. Buchsbaum L.A. Jeu I. Nenadic M.B. Fleischman L. Shihabuddin M.M. Haznedar P.D. Harvey Hypofrontality in unmedicated schizophrenia patients studied with PET during performance of a serial verbal learning task Schizophr Res 43 2000 33-46
30. H.-P. Volz C. Gaser F. Hager R. Rzanny J. Ponisch H.-J. Mentzel W.A. Kaiser H. Sauer Decreased frontal activation in schizophrenics during stimulation with the Continuous Performance Test - a functional magnetic resonance imaging study Eur Psychiatry 14 1999 17-24
31. M.S. Buchsbaum E.A. Hazlett Positron emission tomography studies of abnormal glucose metabolism in schizophrenia Schizophr Bull 24 1998 343-364
32. J. Schroder M.S. Buchsbaum B.V. Siegel F.J. Geider J. Lohr C. Tang J. Wu S.G. Potkin Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia Schizophr Res 19 1996 41-53
33. A. Wolkin M. Sanfilipo A.P. Wolf B. Angrist J.D. Brodie J. Rotrosen Negative symptoms and hypofrontality in chronic schizophrenia Arch Gen Psychiatry 49 1992 959-965
34. C.A. Tamminga G.K. Thaker R. Buchanan B. Kirkpatrick L.D. Alphs T.N. Chase W.T. Carpenter Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome Arch Gen Psychiatry 49 1992 522-530
35. S.M. Cochran C.E. McKerchar B.J. Morris J.A. Pratt Induction of differential patterns of local cerebral glucose metabolism and immediate-early genes by acute clozapine and haloperidol Neuropharmacology 43 2002 394-407
36. X.M. Gao T. Hashimoto C.A. Tamminga Phencyclidine (PCP) and dizocilpine (MK801) exert time-dependent effects on the expression of immediate early genes in rat brain Synapse 29 1998 14-28
37. Y. Suzuki E. Jod S. Takeuchi S. Niwa Y. Kayama Acute administration of phencyclidine induces tonic activation of medial prefrontal cortex neurons in freely moving rats Neuroscience 114 2002 769-779
38. F.X. Vollenweider K.L. Leenders C. Scharfetter A. Antonini P. Maguire J. Missimer J. Angst Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG) Eur Neuropsychopharmacol 7 1997 9-24
39. X.M. Gao O. Shirakawa F. Du C.A. Tamminga Delayed regional metabolic actions of phencyclidine Eur J Pharmacol 241 1993 7-15
40. S.M. Cochran M. Fujimura B.J. Morris J.A. Pratt Acute and delayed effects of phencyclidine upon mRNA levels of markers of glutamatergic and GABAergic neurotransmitter function in the rat brain Synapse 46 2002 206-214
41. J.M. Birrell V.J. Brown Medial frontal cortex mediates perceptual attention set shifting in the rat J Neurosci 20 2000 4320-4324
42. Egerton A, Reid L, McKerchar CE, Morris BJ, Pratt JA: Impairment in perceptual attentional set shifting following PCP administration: A rodent model of cognitive dysfunction in schizophrenia. Psychopharmacology (Berl) 2004, in press.
43. S.M. Cochran L.J. Steward M.B. Kennedy C.E. McKerchar J.A. Pratt B.J. Morris Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: Differential modulation by antipsychotic drugs Neuropsychopharmacology 28 2003 265-275
44. G. Keilhoff A. Becker G. Grecksch G. Wolf H.-G. Bernstein Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia Neuroscience 126 2004 591-598
45. Y. Zhu R.L. Stornetta J.J. Zhu Chandelier cells control excessive cortical excitation: Characteristics of whisker-evoked synaptic responses of layer 2/3 nonpyramidal and pyramidal neurons J Neurosci 24 2004 5101-5108
46. R.S. Jones E.H. Buhl Basket-like interneurones in layer II of the entorhinal cortex exhibit powerful NMDA-mediated excitation Neurosci Lett 149 1993 35-39
47. 2+ dynamics J Physiol 551 2003 67-78
48. M.C. Gonzalez-Albo G.N. Elston J. DeFelipe The human temporal cortex: characterization of neurons expressing nitric oxide synthase, neuropeptides and calcium-binding proteins, and their glutamate receptor subunit profiles Cereb Cortex 11 2001 1170-1181
49. M. Kondo R. Sumino H. Okado Combinations of AMPA receptor subunit expression in individual cortical neurons correlate with expression of specific calcium-binding proteins J Neurosci 17 1997 1570-1581
50. K. Toth G. Suares J.J. Lawrence E. Philips-Tansey C.J. McBain Differential mechanisms of transmission at three types of mossy fiber synapse J Neurosci 20 2000 8279-8289
51. E.C. Fuchs H. Doheny H. Faulkner A. Caputi R.D. Traub A. Bibbig N. Kopell M.A. Whittington H. Monyer Genetically altered AMPA-type glutamate receptor kinetics in interneurons disrupt long-range synchrony of gamma oscillation Proc Natl Acad Sci USA 98 2001 3571-3576
52. M.O. Cunningham M.A. Whittington A. Bibbig A. Roopun LeBeau FEN A. Vogt H. Monyer E.H. Buhl R.D. Traub A role for fast rhythmic bursting neurons in cortical gamma oscillations in vitro Proc Natl Acad Sci USA 101 2004 7152-7157
53. J.C. Hirsch F. Crepel Blockade of NMDA receptors unmasks a long-term depression in synaptic efficacy in rat prefrontal neurons in vitro Exp Brain Res 85 1991 621-624
54. T.G.M. van Erp P.A. Saleh I.M. Rosso M. Huttunen J. Lonnqvist T. Pirkola O. Salonen L. Valanne V.-P. Poutanen C.-G. Standertskjold-Nordenstam et al. Contributions of genetic risk and fetal hypoxia to hippocampal volume in patients with schizophrenia or schizoaffective disorder, their unaffected siblings, and healthy unrelated volunteers Am J Psychiatry 159 2002 1514-1520
55. H. Kunugi T. Urushibara R.M. Murray S. Nanko T. Hirose Prenatal underdevelopment and schizophrenia: A case report of monozygotic twins Psychiatry Clin Neurosci 57 2003 271-274
56. J.H. Weiss J. Koh K.G. Baimbridge D.W. Choi Cortical neurons containing somatostatin- or parvalbumin-like immunoreactivity are atypically vulnerable to excitotoxic injury in vitro Neurology 40 1990 1288-1292
57. D.A. Cruz S.M. Eggan D.A. Lewis Postnatal development of pre- and postsynaptic GABA markers at chandelier cell connections with pyramidal neurons in monkey prefrontal cortex J Comp Neurol 465 2003 385-400
58. H.B.M. Uylings I. Delalle Z. Petanjek M.J.T. Koenderink Structural and immunocytochemical differentiation of neurons in prenatal and postnatal human prefrontal cortex Neuroembryology 1 2002 176-186
59. Y. Wang P.S. Goldman-Rakic D2 receptor regulation of synaptic burst firing in prefrontal cortical pyramidal neurons Proc Natl Acad Sci USA 101 2004 5093-5098
60. P. Calabresi A. Saiardi A. Pisani J.-H. Baik D. Centonze N.B. Mercuri G. Bernardi E. Borrelli Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors J Neurosci 17 1997 4536-4544
61. K.S. Hsu Characterization of dopamine receptors mediating inhibition of excitatory synaptic transmission in the rat hippocampal slice J Neurophysiol 76 1996 1887-1895
62. U. Heresco-Levy D.C. Javitt Comparative effects of glycine and -cycloserine on persistent negative symptoms in schizophrenia: A retrospective analysis Schizophr Res 66 2004 89-96